Press Release | 05/20/2020
BERKELEY, Calif. and VANCOUVER, British Columbia, May 20, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining a novel vaccine platform to selectively deliver antigens of interest to immune cells to induce immune responses toward pathogens including SARS-CoV-2 virus or cancer cells, or reduce immune responses in the case of autoimmune or allergic diseases.
The patent application, entitled “MULTI-VALENT IMMUNOSTIMULATORS FOR INFECTIOUS DISEASES, AUTOIMMUNE DISEASES, ALLERGIC DISEASES AND CANCER”, describes a platform to generate multi-valent reagents carrying an antigen (such as an antigen from SARS-CoV-2) and delivering it to immune cells such as dendritic cells, a type of antigen-presenting cell crucial for the induction and modulation of immune responses. The expected effect is a targeted therapy envisioned to selectively destroy infectious agents or cancer cells with minimal negative effect on normal cells. This may mean less severe side effects for the treated patients compared to other therapies. The technology also has uses for autoimmune diseases and allergic diseases. The Company cautions that these novel therapeutics are still under early-stage research and development and is not making any express or implied claims as to their success in cancer treatment or commercial viability. The patent application seeks protection for, among others, the design of new therapeutics and methods for their use.
BriaCell has recently filed several provisional patent applications related to (1) immunotherapy; (2) antibody-based treatment; and (3) antigen-based induction of immune response, including:
Patent Application 1 (April 14, 2020 press release): Immunotherapy Approach
“INDUCING IMMUNE RESPONSES BY TRANSFORMING CANCER CELLS INTO ANTIGEN-PRESENTING CELLS”;
Based on molecular analyses of BriaCell’s whole-cell immunotherapy anti-tumor product candidate, designed to stimulate the immune system to recognize and destroy the patient’s tumors by acting as antigen-presenting cells.
Patent Application 2 (April 21, 2020 press release): Antibody-Based Treatment Approach
“COMPUTER-GUIDED DESIGN OF ANTIBODIES INCLUDING NEUTRALIZING SARS-CoV-2 BINDING AGENTS”;
Antibodies designed and selected to neutralize SARS-CoV-2 using computer simulation – envisioned to prevent and treat the life-threatening symptoms of COVID-19;
BriaCell hypothesizes that antibodies may quickly and specifically recognize the SARS-CoV-2 virus, bind to it, and neutralize it.
Patent Application 3 (May 20, 2020 press release): Antigen-Based Immune Response Approach
“MULTI-VALENT IMMUNOSTIMULATORS FOR INFECTIOUS DISEASES, AUTOIMMUNE DISEASES, ALLERGIC DISEASES AND CANCER”;
Platform to generate multi-valent reagents carrying an antigen (such as an antigen from SARS-CoV-2) and delivering it to immune cells to induce (or dampen) immune responses;
Anticipated effect is a targeted therapy envisioned to selectively destroy infectious agents or cancer cells with minimal negative effect on normal cells.
The Company cautions that COVID-19 therapeutic development is still under early-stage research and development and is not making any express or implied claims that it has the ability to treat, prevent or eliminate the COVID-19 virus at this time.
The Company’s scientific experts have read and approved the scientific disclosures contained in the press release.
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
For additional information on BriaCell, please visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation (also known as "forward-looking statements") which are subject to known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company's public filings available at www.sedar.com.
These forward-looking statements include, but are not limited to, BriaCell’s plans, objectives, expectations and intentions. Such forward-looking statements reflect BriaCell's current beliefs and are based on information currently available to management. Although the forward-looking statements contained in this news release are based upon what BriaCell believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics Corp.:
William V. Williams, MD
President & CEO
Recent BCTX News
- BriaCell Announces Oral and Poster Presentations at ASCO 2024 • GlobeNewswire Inc. • 04/24/2024 12:00:33 PM
- BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference • GlobeNewswire Inc. • 03/06/2024 01:00:26 PM
- BriaCell Provides Update on Alleged Illegal Trading of Public Securities • GlobeNewswire Inc. • 02/27/2024 01:00:00 PM
- BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case • GlobeNewswire Inc. • 02/07/2024 01:00:37 PM
- Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing • GlobeNewswire Inc. • 02/06/2024 01:30:53 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:24:58 PM
- BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting • GlobeNewswire Inc. • 01/31/2024 03:48:36 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/22/2024 10:00:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/09/2024 09:05:36 PM
- BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer • GlobeNewswire Inc. • 01/04/2024 01:45:00 PM
- BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients • GlobeNewswire Inc. • 12/28/2023 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:38 PM
- BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset • GlobeNewswire Inc. • 12/20/2023 01:40:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/14/2023 10:00:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 10:00:35 PM
- BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS • GlobeNewswire Inc. • 12/06/2023 02:31:11 PM
- BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit • GlobeNewswire Inc. • 12/06/2023 02:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 12:00:38 PM
- BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor • GlobeNewswire Inc. • 11/30/2023 12:00:00 PM
- BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND • GlobeNewswire Inc. • 11/03/2023 12:31:01 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM